Seoul, South Korea

Yeong Wook Song

USPTO Granted Patents = 3 

 

Average Co-Inventor Count = 2.3

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2017-2024

Loading Chart...
Loading Chart...
3 patents (USPTO):Explore Patents

Title: Yeong Wook Song: Innovator in Biopharmaceuticals

Introduction

Yeong Wook Song is a prominent inventor based in Seoul, South Korea. He has made significant contributions to the field of biopharmaceuticals, particularly in the development of innovative treatments for rheumatoid arthritis. With a total of 3 patents to his name, his work is paving the way for new therapeutic options.

Latest Patents

One of his latest patents is titled "Peptide for treating rheumatoid arthritis and use thereof." This invention provides a peptide consisting of specific amino acid sequences that can be used in pharmaceutical compositions aimed at treating rheumatoid arthritis. Another notable patent is the "Anti-TNF-α/CXCL10 double-targeting antibody and use thereof." This invention relates to a bispecific antibody that effectively binds to both TNF-α and CXCL10, demonstrating excellent inhibitory activity and potential for treating immunological diseases.

Career Highlights

Yeong Wook Song has worked with notable organizations such as the Snur & Db Foundation and Seoul National University. His experience in these institutions has allowed him to collaborate on various research projects that focus on innovative medical solutions.

Collaborations

Some of his coworkers include Joo Youn Lee and Eugene C Yi. Their collaborative efforts have contributed to the advancement of research in the field of immunology and biopharmaceuticals.

Conclusion

Yeong Wook Song's innovative work in developing treatments for rheumatoid arthritis showcases his dedication to improving healthcare through scientific research. His contributions are significant in the ongoing quest for effective therapies in the biopharmaceutical industry.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…